Abstract
Background There are some concerns about the effectiveness of the inactivated and vector-based vaccines against SARS-CoV-2 in the real-world settings with the emergence of new mutations, especially variants of concern. Data derived from administrative repositories during mass-vaccination campaigns or programs are of interest to study vaccine effectiveness (VE).
Methods Using 4-repository administrative data linkage, we conducted a historical cohort study on a target population of 3,628,857 inhabitants aged at least 18 years residing in Southern Iran.
Results We estimated 71.9% [95% CI: 70.7-73.1%], 81.5% [95% CI: 79.5-83.4%], 67.5% [95% CI: 59.5-75.6%], and 86.4% [95% CI: 84.1-88.8%] hospitalization reduction for those who received the full vaccination schedule of BIBP-CorV, ChAdOx1-S/nCoV-19, rAd26-rAd5, and BIV1-CovIran vaccines, respectively. A high reduction in mortality – at least 85% – was observed in all age subgroups of fully immunized population.
Conclusion The pragmatic implementation of a vaccination plan including all available vaccine options in the Iranian population was associated with a significant reduction in documented COVID-19 infection, hospitalization, and death associated with COVID-19.
Key points The mass vaccination program with implementing a group of vaccines, that even for some of them (rAd26-rAd5, and BIV1-CovIran vaccines) have been only regionally authorized for emergency use, has been associated with a dramatic reduction in documented COVID-19 infection, as well as in hospitalization and deaths related to the COVID-19 diagnosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was not financially supported.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Biomedical Research Ethics Committees of Shiraz University of Medical Sciences gave ethical approval for this work (code: IR.SUMS.REC.1400.486; link: ethics.research.ac.ir/PortalProposalList.php?code=&title=%C7%CB%D1%C8%CE%D4%26%231740%3B&name=%E3%DE%CF%E3%26%231740%3B&stat=&isAll=&GlobalBackPage=https%3A%2F%2Fethics.research.ac.ir%2FPortalCommittee.php%3Fpage%3D3%26perPage%3D100%26order%3D%26lastorder%3D%26code%3DIR.SUMS.MED.REC)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Alternate author: Alireza Heiran, M.D., Non-communicable Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. PO: 7193635899; Tel.: +987136122302; Fax: +987136122302; Mobile Tel.: +989178326026. E-mail: heiran.alireza{at}gmail.com,
Data Availability
The data repositories generated during the current study are not publicly available; however, would be available from the corresponding author on reasonable request to the Shiraz University of Medical Sciences, Vice Chancellor of Research.
